[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SK286898B6 - Fyziologicky aktívny konjugát, prostriedok a spôsob prípravy - Google Patents

Fyziologicky aktívny konjugát, prostriedok a spôsob prípravy Download PDF

Info

Publication number
SK286898B6
SK286898B6 SK1035-2001A SK10352001A SK286898B6 SK 286898 B6 SK286898 B6 SK 286898B6 SK 10352001 A SK10352001 A SK 10352001A SK 286898 B6 SK286898 B6 SK 286898B6
Authority
SK
Slovakia
Prior art keywords
conjugates
conjugate
peg
gcsf
integer
Prior art date
Application number
SK1035-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK10352001A3 (sk
Inventor
Pascal Sebastian Bailon
Original Assignee
Amgen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen, Inc. filed Critical Amgen, Inc.
Publication of SK10352001A3 publication Critical patent/SK10352001A3/sk
Publication of SK286898B6 publication Critical patent/SK286898B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Polyethers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
SK1035-2001A 1999-01-29 2000-01-19 Fyziologicky aktívny konjugát, prostriedok a spôsob prípravy SK286898B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11791799P 1999-01-29 1999-01-29
PCT/US2000/001264 WO2000044785A1 (en) 1999-01-29 2000-01-19 Gcsf conjugates

Publications (2)

Publication Number Publication Date
SK10352001A3 SK10352001A3 (sk) 2002-06-04
SK286898B6 true SK286898B6 (sk) 2009-07-06

Family

ID=22375505

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1035-2001A SK286898B6 (sk) 1999-01-29 2000-01-19 Fyziologicky aktívny konjugát, prostriedok a spôsob prípravy

Country Status (26)

Country Link
US (4) US20030130193A1 (cs)
EP (1) EP1157037B1 (cs)
JP (1) JP2002540065A (cs)
KR (1) KR100689212B1 (cs)
CN (1) CN1376164A (cs)
AT (1) ATE246202T1 (cs)
AU (1) AU2618500A (cs)
BG (1) BG65213B1 (cs)
BR (1) BR0007781A (cs)
CA (1) CA2361766C (cs)
CZ (1) CZ300546B6 (cs)
DE (1) DE60004172T2 (cs)
DK (1) DK1157037T3 (cs)
EA (2) EA004685B1 (cs)
ES (1) ES2204509T3 (cs)
HK (1) HK1049673A1 (cs)
HU (1) HU228488B1 (cs)
IL (1) IL144361A0 (cs)
MX (1) MXPA01007609A (cs)
NO (1) NO331787B1 (cs)
NZ (1) NZ513113A (cs)
PT (1) PT1157037E (cs)
RS (1) RS50928B (cs)
SK (1) SK286898B6 (cs)
WO (1) WO2000044785A1 (cs)
ZA (1) ZA200105932B (cs)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300546B6 (cs) * 1999-01-29 2009-06-10 Amgen, Inc. Fyziologicky aktivní konjugát, prostredek a zpusob prípravy
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
ES2320101T3 (es) 2000-10-16 2009-05-19 Chugai Seiyaku Kabushiki Kaisha Eritropoyetina conjugada con mono-peg.
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
DK1578771T3 (da) * 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
DK2279755T3 (da) * 2001-10-10 2014-05-26 Ratiopharm Gmbh Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF)
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
AP2004003050A0 (en) * 2001-11-20 2004-06-30 Pharmacia Corp Chemically modified human growth hormone conjugates
EP1526872A1 (en) * 2002-07-24 2005-05-04 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EP1667706A4 (en) * 2003-08-22 2009-06-24 Queensland Inst Med Res G-CSF DERIVATIVE FOR INDUCING IMMUNOLOGICAL TOLERANCE
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US20060174362A1 (en) * 2005-02-01 2006-08-03 Origen Therapeutics, Inc. Long-term culture of avian primordial germ cells (PGCs)
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1888119B1 (en) 2005-06-01 2011-03-09 Maxygen, Inc. Pegylated g-csf polypeptides and methods of producing same
PL2279758T3 (pl) 2005-06-16 2015-07-31 Nektar Therapeutics Koniugaty mające degradowalne połączenie oraz odczynniki polimerowe użyteczne w wytwarzaniu takich koniugatów
KR20080033439A (ko) * 2005-08-04 2008-04-16 넥타르 테라퓨틱스 에이엘, 코포레이션 G-csf 부분 및 중합체의 컨주게이트
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP2007112924A (ja) * 2005-10-21 2007-05-10 National Institute For Materials Science 高分子架橋剤及びこの架橋剤を用いたリポソーム又は細胞の架橋体
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN101002943B (zh) * 2006-01-17 2012-02-01 中国科学院过程工程研究所 支链peg-gcsf和peg-gmcsf结合物及其制备方法
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US20100316631A1 (en) * 2006-10-19 2010-12-16 The Uab Research Foundation Water Soluble Curcumin-Based Compounds
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
JP2008125952A (ja) * 2006-11-24 2008-06-05 National Institute For Materials Science 複合架橋体
CN101245109B (zh) * 2007-02-12 2011-12-14 杭州九源基因工程有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
EA017770B1 (ru) 2007-04-03 2013-03-29 Биодженерикс Аг Способы лечения с использованием гликопэгилированного g-csf
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
CL2008002054A1 (es) 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
AR067537A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
CN101352573B (zh) * 2007-07-27 2011-02-09 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
ES2523030T3 (es) 2008-02-18 2014-11-20 Jiangsu Hengrui Medicine Co., Ltd. Un conjugado del G-CSF modificado por un polímero hidrosoluble
AU2009219232B2 (en) 2008-02-27 2014-02-27 Novo Nordisk A/S Conjugated Factor VIII molecules
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
WO2010034442A1 (en) 2008-09-23 2010-04-01 F. Hoffmann-La Roche Ag Purification of erythropoietin
CN102740896B (zh) 2010-02-11 2014-08-27 霍夫曼-拉罗奇有限公司 Igf-i聚乙二醇缀合物
SI2616101T1 (sl) 2010-09-14 2014-10-30 F. Hoffmann-La Roche Ag Postopek za čiščenje pegiliranega eritropoetina
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
AU2017295037B2 (en) 2016-07-15 2021-07-22 F. Hoffmann-La Roche Ag Method for purifying PEGylated erythropoietin
WO2019075053A1 (en) * 2017-10-11 2019-04-18 Elanco Us Inc. PORCINE G-CSF VARIANTS AND USES THEREOF
SG11202005990RA (en) 2017-12-29 2020-07-29 Hoffmann La Roche Process for providing pegylated protein composition
CN111727063A (zh) 2017-12-29 2020-09-29 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
KR102500631B1 (ko) 2017-12-29 2023-02-15 에프. 호프만-라 로슈 아게 페길화 단백질 조성물의 제공 방법
US20220227805A1 (en) * 2020-12-23 2022-07-21 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1609546A (en) * 1925-11-19 1926-12-07 Petroleum Rectifying Co Process of separating water from emulsions
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4514497B1 (en) * 1983-12-30 1998-02-24 Novagene Inc Modified live pseudorabies viruses
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Peg化したヒト顆粒球コロニー刺激因子の定量法
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
KR0176625B1 (ko) * 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
CZ300546B6 (cs) * 1999-01-29 2009-06-10 Amgen, Inc. Fyziologicky aktivní konjugát, prostredek a zpusob prípravy

Also Published As

Publication number Publication date
SK10352001A3 (sk) 2002-06-04
EP1157037B1 (en) 2003-07-30
HUP0203652A3 (en) 2005-01-28
NO20013700D0 (no) 2001-07-27
NO20013700L (no) 2001-09-25
AU2618500A (en) 2000-08-18
CZ300546B6 (cs) 2009-06-10
KR20020007296A (ko) 2002-01-26
NZ513113A (en) 2004-03-26
EA200400067A1 (ru) 2004-04-29
BG65213B1 (bg) 2007-07-31
KR100689212B1 (ko) 2007-03-09
BR0007781A (pt) 2002-02-05
YU54301A (sh) 2003-10-31
US20050196378A1 (en) 2005-09-08
EA200100838A1 (ru) 2002-04-25
NO331787B1 (no) 2012-04-02
DE60004172T2 (de) 2004-04-22
US20070219356A1 (en) 2007-09-20
JP2002540065A (ja) 2002-11-26
CZ20012654A3 (cs) 2002-05-15
HU228488B1 (en) 2013-03-28
HK1049673A1 (zh) 2003-05-23
ES2204509T3 (es) 2004-05-01
HUP0203652A2 (hu) 2003-03-28
US20080287659A1 (en) 2008-11-20
IL144361A0 (en) 2002-05-23
CA2361766C (en) 2011-12-06
EP1157037A1 (en) 2001-11-28
CN1376164A (zh) 2002-10-23
PT1157037E (pt) 2003-12-31
CA2361766A1 (en) 2000-08-03
WO2000044785A1 (en) 2000-08-03
MXPA01007609A (es) 2003-06-24
DK1157037T3 (da) 2003-11-24
BG105851A (en) 2002-06-28
RS50928B (sr) 2010-08-31
US20030130193A1 (en) 2003-07-10
ATE246202T1 (de) 2003-08-15
PL363117A1 (en) 2004-11-15
EA004685B1 (ru) 2004-06-24
ZA200105932B (en) 2002-10-18
DE60004172D1 (de) 2003-09-04

Similar Documents

Publication Publication Date Title
SK286898B6 (sk) Fyziologicky aktívny konjugát, prostriedok a spôsob prípravy
JP2989002B2 (ja) 化学修飾顆粒球コロニー刺激因子
JP3747070B2 (ja) 改良型インターフェロン−ポリマーコンジュゲート
EP0862455B1 (en) Interferon-polymer conjugates and process for preparing the same
US7893019B2 (en) G-CSF site-specific mono-conjugates
JP5334347B2 (ja) 化学的に修飾した新規なエリスロポエチン刺激タンパク質組成物および方法
US20040030101A1 (en) Interferon conjugates
WO2006095029A2 (en) Di-polymer protein conjugates and processes for their preparation
JP2008543304A (ja) ヒト顆粒球コロニー刺激因子イソ型(HumanGranulocyte−ColonyStimulatingFactorIsoforms)
US20210268117A1 (en) Methods of generating a pegylated il-11 composition
EP1834963A1 (en) Di-polymer protein conjugates and processes for their preparation
US8629104B2 (en) G-CSF and water-soluble polymer conjugate
AU2004233543B2 (en) GCSF Conjugates
US20040204566A1 (en) Chemically-modified G-CSF
EP1369429A1 (en) GCSF conjugates
EP1869079A2 (en) Di-polymer protein conjugates and processes for their preparation
PL203462B1 (pl) Fizjologicznie aktywne koniugaty czynnika stymuluj acego tworzenie kolonii granulocytów (GCSF), zawieraj ace je kompozycje i sposób wytwarzania koniugatu PEG-GCSF
KR20180017104A (ko) Peg화된 과립세포 콜로니 자극 인자(gcsf)
KR20130137966A (ko) 생체적합성 고분자가 접합된 단백질 및 이의 제조방법
MX2007015893A (en) Human granulocyte-colony stimulating factor isoforms

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20200119